Logo image of IGC

IGC PHARMA INC (IGC) Stock Fundamental Analysis

USA - NYSEARCA:IGC - US45408X3089 - Common Stock

0.4062 USD
-0.01 (-2.8%)
Last: 10/10/2025, 2:34:46 PM
Fundamental Rating

1

Taking everything into account, IGC scores 1 out of 10 in our fundamental rating. IGC was compared to 196 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of IGC have multiple concerns. IGC is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

IGC had negative earnings in the past year.
In the past year IGC has reported a negative cash flow from operations.
IGC had negative earnings in each of the past 5 years.
In the past 5 years IGC always reported negative operating cash flow.
IGC Yearly Net Income VS EBIT VS OCF VS FCFIGC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -5M -10M -15M

1.2 Ratios

IGC has a Return On Assets of -81.41%. This is in the lower half of the industry: IGC underperforms 72.45% of its industry peers.
With a Return On Equity value of -112.50%, IGC is not doing good in the industry: 62.76% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -81.41%
ROE -112.5%
ROIC N/A
ROA(3y)-93.23%
ROA(5y)-72.05%
ROE(3y)-122.42%
ROE(5y)-91.4%
ROIC(3y)N/A
ROIC(5y)N/A
IGC Yearly ROA, ROE, ROICIGC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -50 -100 -150

1.3 Margins

IGC has a Gross Margin of 48.70%. This is in the better half of the industry: IGC outperforms 62.24% of its industry peers.
In the last couple of years the Gross Margin of IGC has grown nicely.
The Profit Margin and Operating Margin are not available for IGC so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 48.7%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.84%
GM growth 5Y75.22%
IGC Yearly Profit, Operating, Gross MarginsIGC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -1K -2K -3K

More info and screens

1

2. Health

2.1 Basic Checks

IGC does not have a ROIC to compare to the WACC, probably because it is not profitable.
IGC has more shares outstanding than it did 1 year ago.
IGC has more shares outstanding than it did 5 years ago.
IGC has a worse debt/assets ratio than last year.
IGC Yearly Shares OutstandingIGC Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M
IGC Yearly Total Debt VS Total AssetsIGC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M

2.2 Solvency

IGC has an Altman-Z score of -12.28. This is a bad value and indicates that IGC is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -12.28, IGC is doing worse than 75.00% of the companies in the same industry.
A Debt/Equity ratio of 0.02 indicates that IGC is not too dependend on debt financing.
The Debt to Equity ratio of IGC (0.02) is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF N/A
Altman-Z -12.28
ROIC/WACCN/A
WACC8.75%
IGC Yearly LT Debt VS Equity VS FCFIGC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10M -10M 20M 30M

2.3 Liquidity

A Current Ratio of 1.28 indicates that IGC should not have too much problems paying its short term obligations.
IGC has a worse Current ratio (1.28) than 73.98% of its industry peers.
A Quick Ratio of 0.68 indicates that IGC may have some problems paying its short term obligations.
The Quick ratio of IGC (0.68) is worse than 85.20% of its industry peers.
Industry RankSector Rank
Current Ratio 1.28
Quick Ratio 0.68
IGC Yearly Current Assets VS Current LiabilitesIGC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5M 10M 15M 20M 25M

More info and screens

3

3. Growth

3.1 Past

IGC shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 57.85%, which is quite impressive.
The Revenue has decreased by -5.50% in the past year.
IGC shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -20.77% yearly.
EPS 1Y (TTM)57.85%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%33.33%
Revenue 1Y (TTM)-5.5%
Revenue growth 3Y47.02%
Revenue growth 5Y-20.77%
Sales Q2Q%20.59%

3.2 Future

The Earnings Per Share is expected to grow by 10.20% on average over the next years. This is quite good.
Based on estimates for the next years, IGC will show a quite strong growth in Revenue. The Revenue will grow by 9.74% on average per year.
EPS Next Y30.18%
EPS Next 2Y10.2%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year4.61%
Revenue Next 2Y9.74%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
IGC Yearly Revenue VS EstimatesIGC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2M 4M 6M
IGC Yearly EPS VS EstimatesIGC Yearly EPS VS EstimatesYearly EPS VS Estimates 2024 2025 2026 2027 -0.05 -0.1 -0.15 -0.2

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

IGC reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year IGC is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
IGC Price Earnings VS Forward Price EarningsIGC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
IGC Per share dataIGC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.02 -0.02 0.04 -0.04 0.06 -0.06

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y10.2%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

IGC does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

IGC PHARMA INC

NYSEARCA:IGC (10/10/2025, 2:34:46 PM)

0.4062

-0.01 (-2.8%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)08-14 2025-08-14/amc
Earnings (Next)11-10 2025-11-10
Inst Owners18.55%
Inst Owner ChangeN/A
Ins Owners3.95%
Ins Owner Change0%
Market Cap37.35M
Analysts80
Price Target3.7 (810.88%)
Short Float %0.46%
Short Ratio0.37
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)25.1%
Min EPS beat(2)8.5%
Max EPS beat(2)41.69%
EPS beat(4)3
Avg EPS beat(4)14.89%
Min EPS beat(4)-14.37%
Max EPS beat(4)41.69%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)4.05%
Min Revenue beat(2)0.97%
Max Revenue beat(2)7.13%
Revenue beat(4)3
Avg Revenue beat(4)1.32%
Min Revenue beat(4)-40.88%
Max Revenue beat(4)38.04%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-6.45%
PT rev (3m)-6.45%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)35.39%
EPS NY rev (3m)35.39%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)-10.17%
Revenue NY rev (3m)-10.17%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 29.39
P/FCF N/A
P/OCF N/A
P/B 5.9
P/tB 8.34
EV/EBITDA N/A
EPS(TTM)-0.07
EYN/A
EPS(NY)-0.07
Fwd EYN/A
FCF(TTM)-0.06
FCFYN/A
OCF(TTM)-0.05
OCFYN/A
SpS0.01
BVpS0.07
TBVpS0.05
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -81.41%
ROE -112.5%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 48.7%
FCFM N/A
ROA(3y)-93.23%
ROA(5y)-72.05%
ROE(3y)-122.42%
ROE(5y)-91.4%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.84%
GM growth 5Y75.22%
F-Score3
Asset Turnover0.15
Health
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 77.99%
Cap/Sales 37.92%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.28
Quick Ratio 0.68
Altman-Z -12.28
F-Score3
WACC8.75%
ROIC/WACCN/A
Cap/Depr(3y)84.26%
Cap/Depr(5y)139.57%
Cap/Sales(3y)48.11%
Cap/Sales(5y)101.2%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)57.85%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%33.33%
EPS Next Y30.18%
EPS Next 2Y10.2%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-5.5%
Revenue growth 3Y47.02%
Revenue growth 5Y-20.77%
Sales Q2Q%20.59%
Revenue Next Year4.61%
Revenue Next 2Y9.74%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y17.86%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y7.65%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y7.77%
OCF growth 3YN/A
OCF growth 5YN/A